Sign up Australia
Proactive Investors - Run By Investors For Investors

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited (ASX:ANP) is preparing to outline details in relation to the ATL1103 program for multiple sclerosis.

Antisense has been granted a trading halt to prepare, with its shares placed in pre-open.

The halt will remain in place until the opening of trade on Wednesday 9th March 2016, or earlier if an announcement is made to the market.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full ANP profile

Antisense Therapeutics Timeline

Related Articles

Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
picture of cells under microscope
December 01 2016
Vaxil is testing Immucin in combination with other immunotherapy modalities
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.